ARTICLE | Clinical News
OncoMed's rosmantuzumab lacks clinical benefit in Phase I for solid tumors
January 12, 2018 6:13 PM UTC
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said IV rosmantuzumab (OMP-131R10) every two weeks "failed to provide compelling evidence of clinical benefit" in an open-label, U.S. Phase Ia/Ib trial to t...
BCIQ Target Profiles